Overcoming chemotherapy resistance

Our goal at Scandion Oncology is to develop drugs that specifically target chemotherapy resistance mechanisms. Improving the outcome and quality of life for cancer patients is our mission.

Drug resistance is one of the most significant challenges for successful medical treatment in oncology. Right now, half of all cancer patients fail chemotherapy.

Although many cancer patients initially benefit from chemotherapy, a large proportion develop resistance against chemotherapy drugs. Few of these patients survive.

Read more about us
10. Nov 20

InvestorUgen hos Dansk Aktionærforening

Bo Rode Hansen presented at InvestorUgen at Dansk Aktionærforening
20. Nov 20

Scandion Oncology webcast

Scandion Oncology presented highlights from Q3, 2020
24. Nov 20

Aktieportfölje Live

Bo Rode Hansen has presented at Aktieportföljen Live.  
25. Nov 20

Life Science Investor Konference

Company update by CEO Bo Rode Hansen.
02. Dec 20

BioStock Live med Scandion Oncology

BioStock Studio: Scandion Oncology outlines vision to fight cancer drug resistance
02. Dec 20

Nordnet Live

Scandion Oncology presentation by CEO Bo Rode Hansen
07. Dec 20

Ophelia Invest Talks

Bliv klogere på biotek branchen og særligt på biotekselskabet Scandion Oncology.
08. Dec 20

MVA Oncology Network

Jan Stenvang will be presenting at MVA webinar at 15:50 – 16:00 (CET)
09. Dec 20

San Antonio Breast Cancer Symposium

Jan Stenvang will present a poster
10. Feb 21

Swiss Nordic Bio

Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting healthcar...

Stay updated with our newsletter

Get notified on mail, when news or press release is posted on our website.

First-in-class cancer treatment

Scandion Oncology will provide new cancer treatments to help overcome chemotherapy resistance for thousands of patients.

Detailed analyses estimate the market to be more than EUR 4 billion annually.

Fast and low-cost track to results

We aim to conclude one Phase II trial within the next two years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Forceful and attractive patents

Scandion Oncology has a forceful patent portfolio lasting until 2037. The patents could be attractive for big pharma to combine with existing cancer treatments.

Pipeline

Scandion Oncology has two promising compounds in the pipeline, including SCO-101, which has completed four Phase I trials, and SCO-201, which is in preclinical testing stages. We aim to conclude one Phase II trial within the next 2 years. Upon conclusion of the Phase II trial, we will be ready to consider exit or partner options.

Clinical Trials

Our lead compound – SCO-101 – has been shown to enhance the effect of certain standard chemotherapy when given in combination. We are planning two Phase II trials within metastatic colorectal cancer and metastatic breast cancer. We are simultaneously developing SCO-201, which will target other solid tumors.

Investors

Detailed analyses suggests the market for Scandion Oncology’s products to be more than EUR 4 billion annually. We believe our patents could be attractive for larger pharmaceutical companies to combine with their existing cancer treatments.

Co-funded by the Horizon 2020 programme of the European Union
Co-funded by the COSME programme of the European Union